Guilhem Roubaud
About
Guilhem Roubaud is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Guilhem Roubaud has authored 132 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 54 papers in Oncology and 42 papers in Surgery. Recurrent topics in Guilhem Roubaud's work include Prostate Cancer Treatment and Research (81 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Guilhem Roubaud is often cited by papers focused on Prostate Cancer Treatment and Research (81 papers), Prostate Cancer Diagnosis and Treatment (33 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Guilhem Roubaud collaborates with scholars based in France, United States and Spain. Guilhem Roubaud's co-authors include Paul Sargos, Karim Fizazi, Shahneen Sandhu, David Olmos, Neal D. Shore, Kim N., Johann S. de Bono, Antoine Thiery-Vuillemin, Carrie A. Adelman and Claire Corcoran and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Guilhem Roubaud
117 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Guilhem Roubaud France | 19 | 1.1k | 702 | 439 | 314 | 281 | 132 | 1.6k | ||
| Naoki Yanagawa Japan | 22 | 949 0.9× | 519 0.7× | 597 1.4× | 285 0.9× | 281 1.0× | 109 | 1.8k | ||
| Pasquale Rescigno Italy | 22 | 773 0.7× | 317 0.5× | 381 0.9× | 397 1.3× | 230 0.8× | 82 | 1.3k | ||
| Dingwei Ye China | 17 | 621 0.6× | 417 0.6× | 502 1.1× | 286 0.9× | 303 1.1× | 88 | 1.2k | ||
| Marcello Tucci Italy | 24 | 1.3k 1.3× | 748 1.1× | 403 0.9× | 369 1.2× | 243 0.9× | 100 | 1.9k | ||
| Bradley Curtis Carthon United States | 20 | 706 0.7× | 922 1.3× | 258 0.6× | 225 0.7× | 455 1.6× | 115 | 1.7k | ||
| Martin Boegemann Germany | 19 | 1.2k 1.1× | 430 0.6× | 228 0.5× | 388 1.2× | 147 0.5× | 90 | 1.4k | ||
| Akira Nagahara Japan | 22 | 547 0.5× | 400 0.6× | 546 1.2× | 344 1.1× | 252 0.9× | 75 | 1.3k | ||
| Sebastian Rogenhofer Germany | 22 | 1.0k 1.0× | 267 0.4× | 808 1.8× | 381 1.2× | 184 0.7× | 40 | 2.0k | ||
| Gaetano Aurilio Italy | 18 | 730 0.7× | 725 1.0× | 318 0.7× | 529 1.7× | 201 0.7× | 65 | 1.4k | ||
| Nabil Adra United States | 19 | 622 0.6× | 460 0.7× | 313 0.7× | 146 0.5× | 757 2.7× | 119 | 1.4k |
Countries citing papers authored by Guilhem Roubaud
Since
Specialization
Citations
This map shows the geographic impact of Guilhem Roubaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guilhem Roubaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guilhem Roubaud more than expected).
Fields of papers citing papers by Guilhem Roubaud
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Guilhem Roubaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guilhem Roubaud. The network helps show where Guilhem Roubaud may publish in the future.
Co-authorship network of co-authors of Guilhem Roubaud
This figure shows the co-authorship network connecting the top 25 collaborators of Guilhem Roubaud. A scholar is included among the top collaborators of Guilhem Roubaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guilhem Roubaud. Guilhem Roubaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grenga, Lucia, Catherine Dunyach‐Remy, Guilhem Roubaud, et al.. (2025). Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.. Journal of Clinical Oncology. 43(5_suppl). 825–825.
2.
Rathkopf, Dana E., Guilhem Roubaud, Kim N., et al.. (2024). Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. European Urology. 88(4). 359–369.
3.
Roubaud, Guilhem, Gerhardt Attard, Martin Boegemann, et al.. (2024). Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. European Journal of Cancer. 209. 114183–114183.
4.
Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276.
5.
Baboudjian, Michaël, Charles Dariane, Gaëlle Fromont, et al.. (2024). Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review. European Urology Oncology. 7(6). 1228–1245.
6.
Chamorey, Emmanuel, Jean-Marc Ferrero, Hakim Mahammedi, et al.. (2024). Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 25(11). 6058–6058.
7.
Hélissey, Carole, J.P. Maroto Rey, Guilhem Roubaud, et al.. (2024). 1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 35. S996–S997.
8.
Calleris, Giorgio, Thomas Filleron, Claudia Kesch, et al.. (2023). Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol. European Urology Oncology. 7(3). 494–500.
9.
Castro, Elena, Gerhardt Attard, Matthew R. Smith, et al.. (2023). LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. Annals of Oncology. 34. S1326–S1326.
10.
Sandhu, Shahneen, Geoffrey Gotto, Francisco Vera-Badillo, et al.. (2023). 1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC). Annals of Oncology. 34. S993–S993.
11.
Olivier, Patrick, et al.. (2023). 1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France. Annals of Oncology. 34. S983–S983.
12.
Gillessen, Silke, Giuseppe Procopio, Stefanie Hayoz, et al.. (2023). Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). Journal of Clinical Oncology. 41(20). 3608–3615.
13.
Ferrero, Jean-Marc, Hakim Mahammedi, Gwénaëlle Gravis, et al.. (2023). Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 15(2). 651–651.
14.
Fizazi, Karim, Alice Bernard‐Tessier, Guilhem Roubaud, et al.. (2023). Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evidence. 3(1). EVIDoa2300171–EVIDoa2300171.
15.
Ruffion, A., Charles Dariane, Éric Barret, et al.. (2023). Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU). Cancers. 15(22). 5485–5485.
16.
Béchade, Dominique, Carine Bellera, Pippa McKelvie‐Sebileau, et al.. (2022). Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies. Clinics and Research in Hepatology and Gastroenterology. 46(5). 101912–101912.
17.
Fromont, Gaëlle, Jean‐Baptiste Beauval, Éric Barret, et al.. (2021). Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers. 13(17). 4251–4251.
18.
Ploussard, Guillaume, Jean‐Baptiste Beauval, Éric Barret, et al.. (2021). A 5-Year Contemporary Nationwide Evolution of the Radical Prostatectomy Landscape. European Urology Open Science. 34. 1–4.
19.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357.
20.
Guillot, Aline, Philippe Barthélémy, Sylvie Négrier, et al.. (2018). Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical Genitourinary Cancer. 17(1). e38–e43.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Naoki Yanagawa Breakdown of academic impact, for papers by Pasquale Rescigno Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Marcello Tucci Breakdown of academic impact, for papers by Bradley Curtis Carthon Breakdown of academic impact, for papers by Martin Boegemann Breakdown of academic impact, for papers by Akira Nagahara Breakdown of academic impact, for papers by Sebastian Rogenhofer Breakdown of academic impact, for papers by Gaetano Aurilio Breakdown of academic impact, for papers by Nabil Adra